UA92327C2 - Застосування n-арилдіазаспіроциклічних сполук для лікування залежностей - Google Patents

Застосування n-арилдіазаспіроциклічних сполук для лікування залежностей

Info

Publication number
UA92327C2
UA92327C2 UAA200702904A UAA200702904A UA92327C2 UA 92327 C2 UA92327 C2 UA 92327C2 UA A200702904 A UAA200702904 A UA A200702904A UA A200702904 A UAA200702904 A UA A200702904A UA 92327 C2 UA92327 C2 UA 92327C2
Authority
UA
Ukraine
Prior art keywords
compounds
addiction
effective
significant
effects
Prior art date
Application number
UAA200702904A
Other languages
English (en)
Russian (ru)
Inventor
Балвиндер Сингх БХАТТИ
Грегори Дж. Гатто
Йозеф Клюцик
Original Assignee
Таргасепт, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Таргасепт, Инк. filed Critical Таргасепт, Инк.
Publication of UA92327C2 publication Critical patent/UA92327C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Описано спосіб лікування лікарської залежності, нікотинової залежності і/або ожиріння, що включає введення N-арилдіазаспіроциклічної сполуки або її фармацевтично прийнятної солі.Сполука ефективна для інгібування продукування й/або секреції допаміну й, отже, ефективна для пригнічення процесу фізіологічної "компенсації", що пов'язаний з усмоктуванням нікотину й/або заборонених лікарських засобів.Сполука може вводитися в ефективних кількостях для інгібування вивільнення допаміну без помітних небажаних побічних ефектів (наприклад, таких побічних ефектів, як значиме збільшення кров'яного тиску й швидкість серцебиття, значимий негативний вплив на травний тракт і значимий негативний вплив на скелетні м'язи).
UAA200702904A 2004-08-20 2005-08-18 Застосування n-арилдіазаспіроциклічних сполук для лікування залежностей UA92327C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60347904P 2004-08-20 2004-08-20

Publications (1)

Publication Number Publication Date
UA92327C2 true UA92327C2 (uk) 2010-10-25

Family

ID=35447974

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200702904A UA92327C2 (uk) 2004-08-20 2005-08-18 Застосування n-арилдіазаспіроциклічних сполук для лікування залежностей

Country Status (16)

Country Link
US (1) US20060058328A1 (uk)
EP (1) EP1784184A2 (uk)
JP (1) JP2008510711A (uk)
KR (1) KR20070043008A (uk)
CN (1) CN101022801A (uk)
AU (1) AU2005277410B2 (uk)
BR (1) BRPI0514509A (uk)
CA (1) CA2575461A1 (uk)
IL (1) IL180929A0 (uk)
MX (1) MX2007002045A (uk)
NO (1) NO20070979L (uk)
NZ (1) NZ552792A (uk)
RU (1) RU2387647C9 (uk)
UA (1) UA92327C2 (uk)
WO (1) WO2006023630A2 (uk)
ZA (1) ZA200701193B (uk)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DK1578422T3 (da) * 2002-12-20 2007-07-02 Niconovum Ab Fysisk og kemisk stabilt nikotin-indeholdende partikelholdigt materiale
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ 改善された嗅ぎたばこ組成物
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
WO2008096746A1 (ja) * 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited スピロ化合物およびその用途
CN101951773A (zh) * 2008-01-15 2011-01-19 塔加西普特公司 7-(3-吡啶基)-1,7-二氮杂螺[4.4]壬烷的制备和对映体分离以及外消旋体和对映体的新的盐形式
CN102070640A (zh) * 2009-11-24 2011-05-25 上海药明康德新药开发有限公司 一种1,7-二氮杂螺[4,5]壬烷及其衍生物的合成方法
SG185643A1 (en) * 2010-05-27 2012-12-28 Targacept Inc Nicotinic receptor non-competitive antagonists
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
CN102516146B (zh) * 2011-11-24 2013-10-02 爱斯特（成都）生物制药有限公司 5位为氮的四元氮杂螺环衍生物及其制备方法和用途
GB201416351D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
GB201416352D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
RU2635105C1 (ru) * 2016-07-15 2017-11-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный университет" Способ получения 4-арил-2,7,9-триазаспиро[4.5]декан-6,8,10-трионов
US11299495B2 (en) * 2016-08-01 2022-04-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CA3181162A1 (en) 2020-06-05 2021-12-09 Stephen W. Kaldor Inhibitors of fibroblast growth factor receptor kinases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282947A (en) * 1962-05-17 1966-11-01 Geschickter Fund Med Res Unsymmetrically substituted 3, 9-diazaspiro(5, 5)undecane compounds
US4922901A (en) * 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
DE69318854T2 (de) * 1993-03-04 1998-10-08 Pfizer Spiroazacyclischderivate als substanz p antagonisten
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US6022868A (en) * 1995-06-29 2000-02-08 Novo Nordisk Als Substituted azacyclic or azabicyclic compounds
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5733912A (en) * 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
DE69900220T2 (de) * 1998-06-12 2002-05-08 F. Hoffmann-La Roche Ag, Basel Diaza-spiro[3,5]nonan-Derivate
EP1224186B1 (en) * 1999-10-27 2003-09-24 Millennium Pharmaceuticals, Inc. Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
WO2001077100A2 (en) * 2000-04-10 2001-10-18 Pfizer Products Inc. Benzoamide piperidine compounds as substance p antagonists
SI1519939T1 (sl) * 2002-07-05 2010-04-30 Targacept Inc N-aril diazaspiracikliŽŤne spojine in postopki za njihovo pripravo in njihova uporaba

Also Published As

Publication number Publication date
MX2007002045A (es) 2007-03-29
ZA200701193B (en) 2009-09-30
WO2006023630A3 (en) 2006-05-04
EP1784184A2 (en) 2007-05-16
AU2005277410B2 (en) 2010-06-24
WO2006023630A2 (en) 2006-03-02
RU2387647C9 (ru) 2011-05-27
IL180929A0 (en) 2007-07-24
JP2008510711A (ja) 2008-04-10
RU2007110020A (ru) 2008-09-27
BRPI0514509A (pt) 2008-06-10
AU2005277410A1 (en) 2006-03-02
CN101022801A (zh) 2007-08-22
KR20070043008A (ko) 2007-04-24
NZ552792A (en) 2009-12-24
US20060058328A1 (en) 2006-03-16
NO20070979L (no) 2007-03-19
RU2387647C2 (ru) 2010-04-27
CA2575461A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
UA92327C2 (uk) Застосування n-арилдіазаспіроциклічних сполук для лікування залежностей
NO20050012L (no) N-aryldiazaspiracykliske forbindelser og fremgangsmater for fremstilling og anvendelse derav
IL295536B2 (en) Specific tryptamines for use in the treatment of mood disorders
EA200800663A1 (ru) Способ и средство профилактики и лечения нарушенного дыхания во время сна
MX2009012558A (es) Combinaciones de farmacos para el tratamiento de distrofia muscular de duchenne.
MX2008016037A (es) Uso de 2-aminotetralinas substituidas para la fabricacion de un medicamento para la prevencion, alivio y/o tratamiento de diversos tipos de dolor.
NO20050569L (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
TW200616974A (en) Chemical compounds
TW200635878A (en) Hydroxybiphenylcarboxylic acids and derivatives, processes for preparing them and their use
EA201100305A1 (ru) Лечение респираторных заболеваний
JP2011500506A5 (uk)
CY1109370T1 (el) Παραγωγα οξαδιαζολονης ως ppar δελτα αγωνιστες
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
MXPA06013221A (es) Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonistas enantiomericamente puros.
SG140605A1 (en) Benzothiazole derivatives
WO2008087461B1 (en) Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis
EA201990419A1 (ru) Слаборастворимый комплекс или его сольват, фармацевтическая композиция и их применение
MXPA05010020A (es) Derivados de oxamida.
RU2016111390A (ru) Неконкурентные антагонисты никотиновых рецепторов
TWI285110B (en) Parkinson disease therapeutic agent
MY129832A (en) Substituted thiophenes, processes for their preparation, their use as medicament or diagnostic and medicament comprising them
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
CA2515730A1 (en) Pyrrolidinohydrochinazolines
CN112209834A (zh) 一种有机亚硝酸根供体及其制备方法与医药用途
RU2014128528A (ru) Лечение диабета I и II типа